Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutive quarters of demand growth. Read the full analysis here.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Geron (GERN) loses 21.2% in 4 weeks, here's why a trend reversal may be around the corner
A downtrend has been apparent in Geron (GERN) lately with too much selling pressure. The stock has declined 21.2% over the past four weeks. However, given the fact that it is now in oversold territory ...
At close: 4:00:01 pm GMT-4 ...
1mon
Geron Corp.
Geron Corp. Annual stock financials by MarketWatch. View the latest GERN financial statements, income statements and financial ratios.
Geron's new CEO has positioned Rytelo as a 2026 growth story, following a lack of sales growth in 2025. GERN announced a restructuring in December and gave some financial guidance in January, ...
Discover real-time Geron Corporation Common Stock (GERN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
Geron (GERN), the biopharmaceutical company behind the approved telomerase inhibitor for specific lower-risk myelodysplastic syndromes, has experienced significant success with its product RYTELO.
At close: 4:00:01 pm GMT-4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results